

References

I-265

1. Budde LE, Assouline S, Shen LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase 1 dose-escalation study. *J Clin Oncol*. 2021; 40:481-491.
2. Lunsumio™ (mosunetuzumab-axgb), injection for intravenous use [package insert]. Genetech, Inc. San Francisco, CA. Revised 12/2022.
3. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Mosunetuzumab-axgb.
4. Micromedex DrugDex Compendium®. 2024. Mosunetuzumab-axgb.
5. National Comprehensive Cancer Network (NCCN). Mosunetuzumab-axgb. NCCN Drugs and Biologics Compendium®. 2024.
6. Mosunetuzumab-axgb In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated January 16, 2023.
7. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. *Lancet Oncol*. 2022;23(8):1055-1065.